News
Adverse effects of antipsychotics in the treatment of schizophrenia negatively affect cognitive functions
Schizophrenia is a severe psychiatric disorder characterized by a wide range of symptoms, with cognitive dysfunctions being one of its domains. Antipsychotics (APs) are used for treatment, but their effectiveness in improving cognitive functions is unclear, and they can simultaneously worsen cognition through their adverse metabolic effects, leading to a reduced lifespan for patients with schizophrenia.
Systemic Manifestations of Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a chronic progressive disease characterized by remodeling…
Safety of Riociguat in the Treatment of Thromboembolic Pulmonary Hypertension in Common Practice
In March 2021, the final safety results of riociguat in the treatment of thromboembolic pulmonary…
Alpha-1-Antitrypsin Deficiency and Its Association with Atopy in Asthmatics
Literature mentions the coincidence of asthma and alpha-1-antitrypsin deficiency, which is caused…
Antiviral and Anti-inflammatory Effects of Alpha-1-Antitrypsin in the Treatment of COVID-19
Human alpha-1-antitrypsin (AAT) is a circulating blood glycoprotein that has been used for decades…
To what extent can the actual level of ALP, ALT, or bilirubin differ from the measured value?
A physician who bases clinical decisions on laboratory-determined values of biological parameters…
Treatment of Motor Symptoms of Parkinson's Disease
Parkinson's disease (PD) is one of the few neurodegenerative disorders for which effective…
Liposomal Pegylated Irinotecan in the Treatment of Pancreatic Tumors
Combined treatment with liposomal pegylated irinotecan, 5-fluorouracil (5-FU), and leucovorin (LV)…
New Treatment Option for Metastatic Pancreatic Cancer – Pegylated Liposomal Irinotecan
The 2019 review article is dedicated to the use of nanoliposomal irinotecan, its toxicity, and its…
What FVIII Levels Are Ideal for Preventing Bleeding in Hemophilia A?
Recent studies indicate that target trough levels of factor 1–3% during prophylactic treatment are insufficient...